Medicare will likely choose the obesity drug semaglutide for price negotiation 'within the next few years,' according to a new analysis from nonpartisan congressional budget experts.
In a social media landscape shaped by hashtags, algorithms, and viral posts, nurse leaders must decide: Will they let the narrative spiral, or can they adapt and join the conversation?
...
